MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 62
- Registration Number
- NCT01268566
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 99
- Registration Number
- NCT01268059
- Locations
- 🇵🇱
Research Site, Szczecin, Poland
A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT01268072
- Locations
- 🇨🇦
Research Site, Sainte-Foy, Quebec, Canada
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsAdvanced Recurrent Ovarian Tumors
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 162
- Registration Number
- NCT01248949
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Other: PlaceboBiological: Benralizumab 2 mgBiological: Benralizumab 100 mgBiological: Benralizumab 20 mg
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 964
- Registration Number
- NCT01238861
- Locations
- 🇷🇺
Research Site, St-Petersburg, Russian Federation
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: PlaceboBiological: Benralizumab 100 mg
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 421
- Registration Number
- NCT01227278
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis
Completed
- Conditions
- Arthritis
- Interventions
- Other: Blood samplesOther: Synovial fluid aspirationOther: Synovial tissue sample
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 23
- Registration Number
- NCT01209585
- Locations
- 🇺🇸
Research Site, Jackson, Tennessee, United States
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
Phase 1
Terminated
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Biological: MEDI-570 0.3 MGOther: PlaceboBiological: MEDI-570 0.03 MGBiological: MEDI-570 0.1 MGBiological: MEDI-570 1 MG
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 44
- Registration Number
- NCT01127321
- Locations
- 🇿🇦
Research Site, Johannesburg, South Africa
A Clinical Study to Assess the Safety of a New Influenza Vaccine
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- Biological: Monovalent Frozen FluMist®Other: Placebo
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2011-07-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT01104493
- Locations
- 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Columbia Research Group, Inc, Portland, Oregon, United States
A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01093040
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath